Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience

Hematol Oncol. 2019 Dec;37(5):641-643. doi: 10.1002/hon.2684. Epub 2019 Nov 7.

Authors

Francesco Autore¹, Alberto Fresa², Idanna Innocenti¹, Annamaria Tomasso², Francesca Morelli², Andrea Corbingi², Federica Sorà¹, Luca Laurenti^{1

2}

Affiliations

¹ Institute of Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
² Institute of Hematology, Università Cattolica del Sacro Cuore, Rome, Italy.

PMID: 31604368
DOI: 10.1002/hon.2684

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage*
Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Agents, Immunological / administration & dosage*
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bone Marrow Purging* / methods
Chlorambucil / administration & dosage
Chlorambucil / therapeutic use*
Drug-Related Side Effects and Adverse Reactions / prevention & control*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Pilot Projects
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Chlorambucil
obinutuzumab